Psoriasis and neurodegenerative diseases—a review

Nowowiejska, Julia; Baran, Anna; Flisiak, Iwona

doi:10.3389/fnmol.2022.917751

Cited by 3 publications

(2 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible relationship of psoriasis and neurodegenerative disorders (NDs) has not been established yet. It is suspected that chronic inflammation and oxidative stress promote ND development in PsO patients in direct and indirect ways, but the evidence is rather weak [54]. The improper homeostasis of fatty-acid-binding proteins (FABPs), glutamic acid (GA), and neurofilament light chain (NFL) have been suggested in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease, and other NDs.…”

Section: Neurodegenerative Diseasesmentioning

confidence: 99%

The Role of Osteopontin in Psoriasis—A Scoping Review

Kimak,

Woźniacka

2024

JCM

View full text Add to dashboard Cite

Psoriasis is a chronic systemic disease with an immunological basis and a complex pathophysiology. The chronic inflammatory status of psoriasis is associated with several comorbidities, such as metabolic syndrome, obesity, and cardiovascular disease. The development of psoriasis is influenced by osteopontin, a glycoprotein that influences physiological and pathological reactions by modulating Th1 and Th17 cellular responses, stimulating keratinocyte proliferation, regulating cellular apoptosis, and promoting angiogenesis. The recent identification of immune pathways involved in psoriasis development has facilitated the development of biological treatments; however, a better understanding of the intricate relationship between underlying inflammatory processes, psoriasis development, and accompanying comorbidities is needed for improved disease management.

show abstract

Section: Neurodegenerative Diseasesmentioning

confidence: 99%

The Role of Osteopontin in Psoriasis—A Scoping Review

Kimak,

Woźniacka

2024

JCM

View full text Add to dashboard Cite

show abstract

“…Another possible explanation for the higher prevalence of mental disorders among patients with psoriasis is the stigmatisation of the disease and sleep disturbances, which lead to increased stress and decreased quality of life [ 11 ]. Furthermore, some studies report that patients who suffer from psoriasis and do not receive systemic treatment had an increased risk of developing Alzheimer’s disease compared to a group not taking such medications [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Kynurenine Pathway in Psoriasis—a Promising Link?

Stepaniuk

Baran

Flisiak

2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis is a common dermatosis which affects the patient’s skin and general well-being because of its link to diseases such as depression, kidney disease and metabolic syndrome. Pathogenesis remains unknown; however, genetic, environmental and immunological factors seem to play a role in the development of the disease. Due to a lack of complete understanding of the psoriasis pathology, effective treatment is yet to be developed. The kynurenine pathway is one of the ways amino acid tryptophan is metabolised. In comorbidities typical for psoriasis such as chronic kidney disease, depression and atherosclerotic alterations in the activation of the kynurenine pathway were observed, which were mainly characterised by higher activity compared to that in healthy individuals. However, the kynurenine pathway has not been thoroughly studied among patients with psoriasis even though increased levels of l -kynurenine, one of the enzymes in the kynurenine pathway, were found in psoriatic skin lesions. Given the unknown pathogenesis of the disease, this finding seems to be a potential new field of study and shows a possible link between psoriasis and its comorbidities that could also lead to novel effective treatment for this chronic condition.

show abstract

Acenocoumarol Exerts Anti-Inflammatory Activity via the Suppression of NF-κB and MAPK Pathways in RAW 264.7 Cells

Han

Hyun

2023

Molecules

View full text Add to dashboard Cite

The repurposing of already-approved drugs has emerged as an alternative strategy to rapidly identify effective, safe, and conveniently available new therapeutic indications against human diseases. The current study aimed to assess the repurposing of the anticoagulant drug acenocoumarol for the treatment of chronic inflammatory diseases (e.g., atopic dermatitis and psoriasis) and investigate the potential underlying mechanisms. For this purpose, we used murine macrophage RAW 264.7 as a model in experiments aimed at investigating the anti-inflammatory effects of acenocoumarol in inhibiting the production of pro-inflammatory mediators and cytokines. We demonstrate that acenocoumarol significantly decreases nitric oxide (NO), prostaglandin (PG)E2, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β levels in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. Acenocoumarol also inhibits the expression of NO synthase (iNOS) and cyclooxygenase (COX)-2, potentially explaining the acenocoumarol-induced decrease in NO and PGE2 production. In addition, acenocoumarol inhibits the phosphorylation of mitogen-activated protein kinases (MAPKs), c-Jun N terminal kinase (JNK), p38 MAPK, and extracellular signal-regulated kinase (ERK), in addition to decreasing the subsequent nuclear translocation of nuclear factor κB (NF-κB). This indicates that acenocoumarol attenuates the macrophage secretion of TNF-α, IL-6, IL-1β, and NO, inducing iNOS and COX-2 expression via the inhibition of the NF-κB and MAPK signaling pathways. In conclusion, our results demonstrate that acenocoumarol can effectively attenuate the activation of macrophages, suggesting that acenocoumarol is a potential candidate for drug repurposing as an anti-inflammatory agent.

show abstract

Psoriasis and neurodegenerative diseases—a review

Cited by 3 publications

References 94 publications

The Role of Osteopontin in Psoriasis—A Scoping Review

The Role of Osteopontin in Psoriasis—A Scoping Review

Kynurenine Pathway in Psoriasis—a Promising Link?

Acenocoumarol Exerts Anti-Inflammatory Activity via the Suppression of NF-κB and MAPK Pathways in RAW 264.7 Cells

Contact Info

Product

Resources

About